154 results on '"Ohba, Shigeo"'
Search Results
2. 10031-GGE-2 GENOMIC ANALYSIS OF MENINGIOMA USING GENE PANEL TESTING
3. TMET-19. TARGETING AMINO ACID METABOLIC VULNERABILITIES IN IDH-MUTANT AND IDH-WILDTYPE GLIOMAS
4. Supplementary table-1 from Mutant IDH1 Cooperates with ATRX Loss to Drive the Alternative Lengthening of Telomere Phenotype in Glioma
5. Supplementary Table S1 from Mutant IDH1 Expression Drives TERT Promoter Reactivation as Part of the Cellular Transformation Process
6. Supplementary Table S1 from Mutant IDH1 Expression Drives TERT Promoter Reactivation as Part of the Cellular Transformation Process
7. Data from Mutant IDH1 Expression Drives TERT Promoter Reactivation as Part of the Cellular Transformation Process
8. Supplementary figure-3 from Mutant IDH1 Cooperates with ATRX Loss to Drive the Alternative Lengthening of Telomere Phenotype in Glioma
9. Supplementary figure-3 from Mutant IDH1 Cooperates with ATRX Loss to Drive the Alternative Lengthening of Telomere Phenotype in Glioma
10. Supplementary table-1 from Mutant IDH1 Cooperates with ATRX Loss to Drive the Alternative Lengthening of Telomere Phenotype in Glioma
11. Data from Mutant IDH1 Expression Drives TERT Promoter Reactivation as Part of the Cellular Transformation Process
12. Supplementary figure-5 from Mutant IDH1 Cooperates with ATRX Loss to Drive the Alternative Lengthening of Telomere Phenotype in Glioma
13. Supplementary figure-2 from Mutant IDH1 Cooperates with ATRX Loss to Drive the Alternative Lengthening of Telomere Phenotype in Glioma
14. Supplementary figure-1 from Mutant IDH1 Cooperates with ATRX Loss to Drive the Alternative Lengthening of Telomere Phenotype in Glioma
15. Supplementary figure-5 from Mutant IDH1 Cooperates with ATRX Loss to Drive the Alternative Lengthening of Telomere Phenotype in Glioma
16. Supplementary figure-4 from Mutant IDH1 Cooperates with ATRX Loss to Drive the Alternative Lengthening of Telomere Phenotype in Glioma
17. Supplementary figure-2 from Mutant IDH1 Cooperates with ATRX Loss to Drive the Alternative Lengthening of Telomere Phenotype in Glioma
18. Supplementary figure-1 from Mutant IDH1 Cooperates with ATRX Loss to Drive the Alternative Lengthening of Telomere Phenotype in Glioma
19. Supplementary figure-4 from Mutant IDH1 Cooperates with ATRX Loss to Drive the Alternative Lengthening of Telomere Phenotype in Glioma
20. Applied Fence-Post Techniques Using Deep Electrodes Instead of Catheters for Resection of Glioma Complicated with Frequent Epileptic Seizures: A Case Report
21. Carotid Plaque Diagnosis With 3-Dimensional Computed Tomography Angiography: A Comparison With Magnetic Resonance Imaging–Based Plaque Diagnosis
22. Three-Dimensional Gradient-Echo–Based Amide Proton Transfer-Weighted Imaging of Brain Tumors: Comparison With Two-Dimensional Spin-Echo–Based Amide Proton Transfer-Weighted Imaging
23. Three-Dimensional Amide Proton Transfer-Weighted Imaging for Differentiating between Glioblastoma, IDH-Wildtype and Primary Central Nervous System Lymphoma
24. Measurement of vessel shape for estimating viscoelastic properties of the radial artery under ultrasound probe pressure
25. LW-8 TREATMENT STRATEGY FOR OLIGODENDROGLIOMAS WITH NEOADJUVANT STRATEGY AND STAGED RESECTION UTILIZING THEIR CHEMOTHERAPEUTIC RESPONSIVENESS
26. CBMS-1 TARGETING GLUTAMINE METABOLISM IN IDH-MUTANT GLIOMAS
27. TMET-18. TARGETING AMINO ACID METABOLIC VULNERABILITIES IN GLIOBLASTOMA
28. Elasticity Measurement of Radial Arterial Wall Considering Vessel Shape Change Caused by Pushing Pressure Applied by Ultrasonic Probe
29. Intracranial phosphaturic mesenchymal tumors. A case report and review of literature
30. Hydrocephalus in Neurofibromatosis Type 1 Caused by a Cyst Formation Similar to Late-Onset Aqueductal Membranous Occlusion: A Case Report and Review of Literature
31. Accurate measurement of elasticity of the radial artery wall considering changes in cross-sectional shape of artery caused by pushing pressure applied by ultrasound probe
32. PKM2 Interacts With the Cdk1-CyclinB Complex to Facilitate Cell Cycle Progression in Gliomas
33. Contrast-Enhanced Magnetic Resonance Imaging, Perfusion Magnetic Resonance Imaging, and 1H-Magnetic Resonance Spectroscopy Distinguish Primary Central Nervous System Vasculitis from Glioblastoma
34. Transsylvian and trans-Heschl’s gyrus approach for a left posterior insular lesion and functional analyses of the left Heschl’s gyrus: illustrative case
35. IDH1-mutant, alternative lengthening of telomeres (ALT)-dependent gliomas use the deubiquitinase BRCC3 to degrade cytosolic cGAS and avoid cGAS-STING-mediated activation of innate immunity
36. Targeting amino acid metabolic vulnerabilities in IDH-mutant and IDH-wildtype gliomas
37. CBMS-1 Targeting amino acid metabolic vulnerabilities in IDH-mutant and IDH-wildtype gliomas
38. TAMI-56. TARGETING AMINO ACID METABOLIC VULNERABILITIES IN IDH-MUTANT AND IDH-WILDTYPE GLIOMAS
39. Primary central nervous system lymphomas with massive intratumoral hemorrhage: Clinical, radiological, pathological, and molecular features of six cases
40. Inhibition of DNA Repair in Combination with Temozolomide or Dianhydrogalactiol Overcomes Temozolomide-Resistant Glioma Cells
41. A subset of PARP inhibitors induces lethal telomere fusion in ALT-dependent tumor cells
42. Association of preoperative seizures with tumor metabolites quantified by magnetic resonance spectroscopy in gliomas
43. Estimation of viscoelasticity of radial artery during flow-mediated dilatation using a single ultrasound probe based on blood pressure measurement via pulse transit time method
44. DDRE-04. THE COMBINED TREATMENT OF L-ASPARAGINASE AND 6-DIAZO-5-OXO-L-NORLEUCINE INHIBIT THE PROLIFERATION OF TEMOZOLOMIDE-SENSITIVE OR RESISTANT GLIOBLASTOMA CELLS
45. Cerebral Tumor with Rhabdoid Features
46. Myoinositol to Total Choline Ratio in Glioblastomas as a Potential Prognostic Factor in Preoperative Magnetic Resonance Spectroscopy
47. MODL-15. THE COMBINATION TREATMENT OF PARP INHIBITOR AND TMZ, OR DAG WILL BE PROMISING TREATMENT IN SF8628
48. Objective and quantitative evaluation of angiographic vascularity in meningioma: parameters of dynamic susceptibility contrast-perfusion-weighted imaging as clinical indicators of preoperative embolization
49. CSIG-19. THE DEUBIQUITINASE BRCC3 LINKS ALT TELOMERES TO SUPPRESSION OF INNATE IMMUNITY IN IDH1-MUTANT GLIOMA
50. DDRE-15. THE COMBINATION THERAPY OF PARP INHIBITOR AND TMZ IN DIFFUSE MIDLINE GLIOMA HARBORING H3 K27M-MUTANT
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.